Supriya Lifescience Limited confirmed that the Hon'ble Supreme Court has admitted its judicial proceedings and granted an interim stay on coercive action against its directors, officers, and officials. This development provides immediate legal relief while the matter remains sub judice.

The company filed an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing serves as a continuation of earlier disclosures regarding the same legal matter.

Judicial Proceedings Status

The Hon'ble Supreme Court has listed the matter for hearing. In the interim period, the court directed that no coercive action shall be taken against the petitioner's directors, officers, or officials. This directive is subject to the specific terms and conditions outlined in the order passed by the court.

The company stated that the matter is presently pending before the Hon'ble Court. It remains under judicial consideration, with no final verdict delivered at this stage.

Compliance and Future Updates

Supriya Lifescience indicated it will continue to monitor the ongoing proceedings closely. The company committed to keeping the stock exchanges and shareholders informed of any material developments. These updates will be provided as and when received from the Hon'ble Court or through other channels in accordance with applicable laws and regulations.

Key Disclosure Details

The disclosure was signed by Prachi Sathe, Company Secretary & Compliance Officer, on October 19, 2026.

Supriya Lifescience Limited filed a petition before the Hon'ble Supreme Court of India on October 8, 2026. This legal move challenges an earlier order issued by the High Court regarding ongoing judicial proceedings involving the company.

The filing serves as a further update to the stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It follows the company's previous intimation on September 23, 2026, which detailed the receipt of the High Court's order.

Legal status and company stance

The matter is currently sub judice and pending consideration before the Supreme Court. Given the active legal proceedings, Supriya Lifescience stated it does not wish to comment further on the merits or potential outcome of the case at this stage.

The company confirmed it will continue to monitor the situation closely. It committed to keeping the stock exchanges and shareholders informed of any material developments as and when updates are received from the court or through other channels in accordance with applicable laws.

Procedural timeline

The progression of this legal dispute highlights the company's strategy to escalate matters beyond the High Court level.

The disclosure was signed by Prachi Sathe, Company Secretary and Compliance Officer, ensuring compliance with regulatory reporting standards for listed entities.